Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients confirmed by sputum cytology);
Pretreated with at least 1 platinum-based chemotherapy;
No previous targeted treatment such as gefitinib, erlotinib;
With a measurable disease(longest diameters \>=10mm with Spiral computed tomography (CT)and \>=20mm with conventional CT) according to RECIST Criteria;
WHO performance status(PS)\<= 2;
Adequate organ functions;
Signed and dated informed consent before the start of specific protocol procedures.
You may not be if
Allergic to icotinib;
Patients with metastatic brain tumors with symptoms;
Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab;
Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.
Clareo Health | High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
